Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Antibody drug conjugates coming to primetime and new agents for breast cancer

Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA

Antibody drug conjugates coming to primetime and new agents for breast cancer ( Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA )

Pancreatic, hepatic and biliary malignancies

Dr Mike Cusnir - Mount Sinai Medical Center, Miami, USA

Pancreatic, hepatic and biliary malignancies ( Dr Mike Cusnir - Mount Sinai Medical Center, Miami, USA )

Intervention of osteoclastogenesis that occurs in breast cancer and multiple...

Dr Gregg Fields - Florida Atlantic University, Florida, USA

Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma ( Dr Gregg Fields - Florida Atlantic University, Florida, USA )

Updates on triple negative breast cancer and immunotherapy

Dr Avan Armaghani - Moffitt Cancer Center, Florida, Miami

Updates on triple negative breast cancer and immunotherapy ( Dr Avan Armaghani - Moffitt Cancer Center, Florida, Miami )

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than...

Prof David Tougeron - Poitiers University Hospital, Poitiers, France

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC ( Prof David Tougeron - Poitiers University Hospital, Poitiers, France )

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2...

Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer ( Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy )

Administering systemic chemotherapy improves survival for patients with...

Dr Giacomo Bregni - Francis Crick Institute, London, England

Administering systemic chemotherapy improves survival for patients with resectable CRCLM ( Dr Giacomo Bregni - Francis Crick Institute, London, England )

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse...

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced...

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )

Isa-VCd induction in NDMM patients with severe renal impairment show no new...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isa-VCd induction in NDMM patients with severe renal impairment show no new safety concerns ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

More from ecancer